PCA3 and pachyonychia congenita: For example, lncRNA PC antigen-3 (PCA-3), approved by the FDA in 2012 as the PROGENSA PCA-3 assay, serves as a urine-based marker for Prostate Cancer (PC) by measuring the ratio of PCA3 to prostate-specific antigen (PSA) levels (161).